Lian-Qu formula treats metabolic syndrome via reducing fat synthesis, insulin resistance and inflammation.
Metabolic syndrome (MetS) is a pathological condition characterized by obesity, hyperglycemia, hypertension and hyperlipidemia that increases the risk of cardiovascular disease, type 2 diabetes and non-alcoholic fatty liver disease. The traditional Chinese medicine Lian-Qu formula (LQF) is modified...
| Published in: | Journal of Ethnopharmacology Vol. 306 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | research Journal Article |
| Published: |
Elsevier B.V.
Apr2023
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162108603&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 162108603 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03788741 3MS jtl: Journal of Ethnopharmacology issn: 03788741 maglogo: N pubinfo: dt: Apr2023 vid: 306 pid: 1004 pub: Elsevier B.V. artinfo: ui: 162108603 162108603 162108603 10.1016/j.jep.2022.116060 162108603 ppct: 1 formats: tig: atl: Lian-Qu formula treats metabolic syndrome via reducing fat synthesis, insulin resistance and inflammation. aug: au: Huang, Rongrong Wang, Baotian He, Jialuo Zhang, Zijun Xie, Rui Li, Senlin Li, Qing Tian, Cheng Tuo, Yali Zheng, Ran Chen, Weihong Xiang, Ming affil: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China sug: subj: Drugs, Chinese Herbal Pharmacodynamics Metabolic Syndrome X Drug Therapy Fats Metabolism Insulin Resistance Inflammation Prevention and Control Network Pharmacology Animal Studies Models, Biological Mice Genes Proteins Metabolism Ontologies Genome Glucose Tolerance Test Sensitivity and Specificity Body Weight Adipose Tissue Distribution Obesity Evaluation Liver Metabolism Staining and Labeling Metabolomics Enzyme-Linked Immunosorbent Assay Polymerase Chain Reaction Tumor Necrosis Factor Interleukins Blood C-Reactive Protein Blood Insulin Sensitivity Hyperlipidemia Prevention and Control Liver Injuries Treatment Outcomes ab: Metabolic syndrome (MetS) is a pathological condition characterized by obesity, hyperglycemia, hypertension and hyperlipidemia that increases the risk of cardiovascular disease, type 2 diabetes and non-alcoholic fatty liver disease. The traditional Chinese medicine Lian-Qu formula (LQF) is modified from Xiaoxianxiong decoction, which has been used for coronary heart disease or metabolic disease in clinical for a long time. However, the pharmacological mechanism of LQF on MetS is unclear. Here, we explored the actions of LQF on MetS via network pharmacology and validated the mechanism in the MetS mice. The chemical components of LQF were searched in the traditional Chinese medicine systems pharmacology database and the natural product activity & species source database. The related targets of MetS disease were gathered from genes cluster with literature profiles database. The protein-protein interaction network was constructed to obtain the key target genes. The Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the key targets were performed to predict the potential mechanisms of LQF action on MetS. And then, the high-fat diet-induced MetS mice were used to validate its therapeutic effect and molecular targets. Insulin tolerance test and oral glucose tolerance test were used to assess insulin sensitivity. Body weight and visceral fat index were measured to assess obesity. Liver metabolism was detected by H&E section, oil red O staining and untargeted lipid metabolomics experiments. Finally, the key targets of LQF action on MetS were verified by PCR and ELISA kits. A total of 466 components in LQF were obtained, among which 71 were active. These components correspond to 74 targets associated with MetS. The predicted targets of LQF worked on MetS were AKT1, INSR, PPARs, FASN, LDLR, TNF, CRP, IL-6, IL-1β and so on. Furthermore, these targets were related to pathways in cellular response to lipid, inflammatory response, glucose transmembrane transport and insulin resistance. Finally, the animal experiments validated that LQF inhibited lipids accumulation by inhibiting the gene expression of FASN and increasing ADPN , and it relieved insulin resistance by increasing GLUT-4 expression. Moreover, LQF alleviated inflammation by reducing IL-6 and CRP levels. LQF exerted anti-MetS effects through improving insulin sensitivity, ameliorating hyperlipidemia and obesity, reducing liver injury, and inhibiting inflammatory response. [Display omitted] • Lian-Qu formula could be successful therapy for metabolic syndrome. • Lian-Qu formula reduced fat synthesis, insulin resistance and inflammation by targeting FASN, ADPN, GLUT-4 genes, IL-6 and CRP. • Provide a research strategy for metabolic syndrome drugs discovery. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|